Early on, IL-1 blockade esp using anakinra, got a lot of attention Canakinumab (CAN-COVID) trial: negative https://t.co/lZnGQEmsJp #ACR21 https://t.co/0QjyWIusH0
@DrAiLynTan @NatRevImmunol https://t.co/QPrCDfjUF4 But canakinumab did not improve survival. What are we still missing?
JAMA CAN-COVID Trial https://t.co/Id9rigvmle Patients hospitalized with severe COVID-19, canakinumab vs placebo, did not significantly increase the likelihood of survival without IMV by D29 (88.8% vs 85.7%, diff 3.1%, OR 1.39, 95% CI 0.76-2.54, p=0.29) htt
$NVS put 223 adult patients “hospitalized with Severe #COVID19 on Placebo or Canakinumab to determine effect on $HGEN Primary endpoint- Survival without Mechanical Ventilation-and $NVS was no better than saline. https://t.co/A1MYsDe8sA $HGEN was 54%+ bette
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe #COVID_19 https://t.co/YdueIta4jX https://t.co/NvHMP9IZpA
In this RCT of 454 patients with severe #COVID19 not requiring invasive mechanical ventilation, treatment with IV #canakinumab did not significantly improve survival without IMV at 29 days. @JAMANetwork https://t.co/MFgPc5PkHi
Otro fracaso. Gracias que tenemos las vacunas
RT @VCUresearch: Congratulations Dr. Antonio Abbate, M.D., Ph.D. for this @JAMA_current publication! Thank you for the groundbreaking and…
RT @VCUresearch: Congratulations Dr. Antonio Abbate, M.D., Ph.D. for this @JAMA_current publication! Thank you for the groundbreaking and…
https://t.co/wVIxtu19Cd サイトカインストームは、IL-1beta drivenではないということか。。。
RT @VCUresearch: Congratulations Dr. Antonio Abbate, M.D., Ph.D. for this @JAMA_current publication! Thank you for the groundbreaking and…
Congratulations Dr. Antonio Abbate, M.D., Ph.D. for this @JAMA_current publication! Thank you for the groundbreaking and important clinical research you have been conducting on the COVID-19 pandemic. Read more about the research here: https://t.co/xSVsn8
Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/mfMwknZyAi via @JAMA_current part of @JAMANetwork
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021;326(3):230–239 https://t.co/0B4jrFCg9z
IL-1betaの阻害薬の重症コロナ患者(低酸素血症)での効果を見たもの。RCT二重盲検。Evidenceとして強い。29日後の生存率に差なし。ただし人工呼吸器が必要でなかった症例が対象。炎症性サイトカイン全部が関係しているわけではないのか?IL-6/JAK系がMain? https://t.co/2icaAPrgEB
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @tipssovetorax: ¿El anticuerpo antiinterleucina 1β, canakinumab es eficaz para tratar a los pacientes hospitalizados con COVID-19 e hipe…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
#canakinumab no better than #placebo for any #covid related #outcome #COVID19 https://t.co/VMUwhJvRCU
RT @YubSedhai: It was a privilege to work in the multicentered Clinical trial during the COVID-19 pandemic. My sincere gratitude to @Abbate…
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
It was a privilege to work in the multicentered Clinical trial during the COVID-19 pandemic. My sincere gratitude to @AbbateAntonio for the opportunity.
RT @AbbateAntonio: (1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/…
RT @tipssovetorax: ¿El anticuerpo antiinterleucina 1β, canakinumab es eficaz para tratar a los pacientes hospitalizados con COVID-19 e hipe…
RT @tipssovetorax: ¿El anticuerpo antiinterleucina 1β, canakinumab es eficaz para tratar a los pacientes hospitalizados con COVID-19 e hipe…
¿El anticuerpo antiinterleucina 1β, canakinumab es eficaz para tratar a los pacientes hospitalizados con COVID-19 e hiperinflamación? en comparación con placebo, no aumentó la sobrevida/2 https://t.co/j2zOcjj92O
Efecto de canakinumab frente a placebo en la supervivencia sin ventilación mecánica invasiva en pacientes hospitalizados con COVID-19 grave. Ensayo clínico al azar/1 https://t.co/j2zOcjj92O
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
(1) Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/0u9wSCZGrs via @JAMA_current part of @JAMANetwork Very proud of this work completed in 2020. Multicenter trial - PI: Roberto Caricchio.
No benefit from blocking IL-1B in preventing the need for mechaniscal ventilation in #COVID19 Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/9G3ovNRLeO via @JAMA_current part of @JAMANet
7-20-2021: In a study just released today from the U.S. & Russia, if Actemra (tocilizumab) can be successfully used against sJIA, AOSD, & the cytokine storm, then why not Ilaris (canakinumab), which also has efficacy against those? https://t.co/5U
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
RT @LChouchana: Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option…
Pas d'efficacité pour cet anti-IL1 dans les formes sévères du #COVID19. Un de plus... la prévention reste la seule option ➡️ #VaccinezVous 💉 🔗 Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.
RT @alimkakeng: The experience of monoclonal abx's show the critical importance of EDs in the Tx of #COVID19 ... Effect of Canakinumab vs…
The experience of monoclonal abx's show the critical importance of EDs in the Tx of #COVID19 ... Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/LjkfKsKhM1 via @JAMA_current part of @JAMA
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @Tuhina_Neogi: Proud that @The_BMC @BUMedicine was the 4th highest recruiting site for this randomized trial of canakinumab in #COVID19.…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
Proud that @The_BMC @BUMedicine was the 4th highest recruiting site for this randomized trial of canakinumab in #COVID19. 80% of our site’s participants were non-English speaking. #Diversity in trials matter.
CAN-COVID trial results published (@Tuhina_Neogi was a PI)
In this study, treatment with #canakinumab for patients with severe #COVID19 did not increase the likelihood of survival without invasive mechanical ventilation Read more from @JAMA_current 👇 https://t.co/iBcG3zpuvl https://t.co/G5xA36Abzg
Randomized clinical trial including 454 patients hospitalized with severe #COVID19 shows that #canakinumab (IL-1 antibody) compared with placebo, did not significantly increase the likelihood of #survival. https://t.co/GGR03dFtb3
RT @HanCardiomd: In severe COVID-19, Tx with #Canakinumab failed to increase the likelihood of survival without Invasive Mechanical Ventila…
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial 重症COVID-19患者に対するIL-1beta抗体であるカナキズマズはプラセボと比べ生存期間に差がなかった https://t.co/atGQCIqyWc
Just out in @JAMA_current , sadly another negative trial. Its clear we need to improve participant heterogeneity to target treatments. Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/eV
RT @HanCardiomd: In severe COVID-19, Tx with #Canakinumab failed to increase the likelihood of survival without Invasive Mechanical Ventila…
In severe COVID-19, Tx with #Canakinumab failed to increase the likelihood of survival without Invasive Mechanical Ventilation at day 29 (CAN-COVID trial) https://t.co/yB1IEyGbhC @JAMA_current @JAMAInternalMed @DrJennHaythe @EricTopol @beaverspharmd @Hin
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @PrathitKulkarni: Negative study for canakinumab (anti-IL-1 antibody) for treatment of #COVID19 👇 https://t.co/iNCWNbY8bR
RT @PrathitKulkarni: Negative study for canakinumab (anti-IL-1 antibody) for treatment of #COVID19 👇 https://t.co/iNCWNbY8bR
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @MatthiasNahrend: Canakinumab is not helpful in severe COVID-19: Effect of Canakinumab vs Placebo on Survival Without IMV in Patients H…
Canakinumab is not helpful in severe COVID-19: Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/axk1s8Uw2W via @JAMA_current part of @JAMANetwork
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
En pacientes hospitalizados con COVID grave, el tratamiento con canakinumab no aumentaría la probabilidad de supervivencia sin ventilación mecánica invasiva el día 29 https://t.co/BomiD7nS0O a través de @JAMA_current part of @JAMANetwork
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
Canakinumab no es mejor que placebo en el aumento de la supervivencia en pacientes con COVID-19 grave sin VMI (dia 29) https://t.co/tzw5aVKa8L vía @JAMA_current part of @JAMANetwork
In this study Canakinumab was no better than placebo https://t.co/g1TvBNmzDu
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial https://t.co/g5pDj23FYJ
Effect of #Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/NljdfEd7QL via @JAMA_current part of @JAMANetwork
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/lY3vOJJKqU via @JAMA_current part of @JAMANetwork
So Canakinumab did not improve survival but... Vaccination can! Cheep and effective @cupallcare Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/Ej0jOlwOf3 via @JAMA_current part of @JAMA
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
重症には抗体療法ダメですね
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
Effect of Canakinumab vs Placebo on Survival Without IMV in Patients Hospitalized With Severe COVID-19 https://t.co/XlvxIz69Fl via @JAMA_current In patients with severe COVID-19, treatment with canakinumab did not significantly ⬆️the likelihood of survival
RT @PrathitKulkarni: Negative study for canakinumab (anti-IL-1 antibody) for treatment of #COVID19 👇 https://t.co/iNCWNbY8bR
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
Negative study for canakinumab (anti-IL-1 antibody) for treatment of #COVID19 👇 https://t.co/iNCWNbY8bR
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
Entre os pacientes hospitalizados graves com # covid19, o tratamento com canakinumab, em comparação com o placebo, não aumentou significativamente a probabilidade de sobrevivência sem ventilação mecânica invasiva no dia 29. https://t.co/1zJUnFscNg
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
No hay diferencia significativa en sobrevida sin ventilación mecánica con el uso de Canakinumab Vs Placebo en pacientes con #COVID19
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
RT @ABsteward: 🆕💥💥 (CAN-COVID) RCT @JAMA_current Effect of anti–interleukin-1β antibody Canakinumab vs Placebo on Survival Without Invasive…
Cakakinumab: no funcional en COVID-19